{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:13:30Z","timestamp":1777936410884,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Subst\ufffdAbuse"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lapse has been one of the major challenges in the treatment of drug dependence sometimes leading to its relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The aim of this study was to determine the lapse rate in drug dependent patients as for the 2 methods of methadone maintenance treatment (MMT) and buprenorphine maintenance treatment (BMT) in Yazd city.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this cross-sectional study, 626 female and male patients who had referred to 5 SUD treatment centers in Yazd and had been treated with methadone and buprenorphine maintenance were studied. Participants were divided into 2 groups of MMT and BMT and were evaluated based on lapse within 6\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In this study, 60.9% of patients were treated with methadone but the rest were treated with buprenorphine. Overall, 33.1% of patients lapsed (35.2% for methadone and 29.8%for buprenorphine). Lapse in methadone treatment was correlated with age, occupational status, and duration of treatment ( P\u2009&lt;\u2009.05); it failed to correlated with any other demographic and clinical characteristics ( P\u2009&gt;\u2009.05). Lapse rate in buprenorphine treatment was also related to marital status and the drug used ( P\u2009&lt;\u2009.05). The mean dose of buprenorphine consumed showed no significant relationship with lapse ( P\u2009&gt;\u2009.05). The results demonstrated that given the low dose, lapse stood higher in the buprenorphine group than the methadone group; however, as to high dose, the buprenorphine group showed lower lapse than the other group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In regard with the high rate of lapse, it is recommended to consider the factors related to the 2 methods of treatments, and provide counseling and training programs to lower lapse in the patients. Ethics Committee (REC) approval code: IR.SSU.REC.1394.158.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11782218221112502","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T07:35:30Z","timestamp":1658475330000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Lapse Rate in Drug Dependent Patients in 2 Methods of Methadone Maintenance Treatment and Buprenorphine Maintenance Treatment"],"prefix":"10.1177","volume":"16","author":[{"given":"Mohammadreza","family":"Vafaeinasab","sequence":"first","affiliation":[{"name":"Physical Medicine and Rehabilitation, Non-communicable Diseases Research Institue, Yazd Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4596-2927","authenticated-orcid":false,"given":"Hamidreza","family":"Zare","sequence":"additional","affiliation":[{"name":"General practitioner, Addiction Therapists Association, Fajr Addiction Treatment Center, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Dehghani","sequence":"additional","affiliation":[{"name":"Epidemiology, Department of Biostatistics and Epidemiology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyedehzahra","family":"Malek","sequence":"additional","affiliation":[{"name":"Social Science, Addiction Therapists Association, Fajr Addiction Treatment Center, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Dehghani-Tafti","sequence":"additional","affiliation":[{"name":"Geriatric Nursing, Non-communicable Diseases Research Institue, Yazd Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadtaghi","family":"Sarebanhassanabadi","sequence":"additional","affiliation":[{"name":"Epidemiology, Non-communicable Diseases Research Institue, Yazd Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"bibr1-11782218221112502","first-page":"67","volume":"5","author":"Fallahzadeh H","year":"2006","journal-title":"Tolooe Behdasht"},{"key":"bibr2-11782218221112502","first-page":"34","volume":"64","author":"Meysamie AP","year":"2006","journal-title":"Tehran Univ Med J"},{"key":"bibr3-11782218221112502","first-page":"611","volume":"25","author":"Botelho \u00c9D","year":"2014","journal-title":"J Braz Chem Soc"},{"key":"bibr4-11782218221112502","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-018-0787-z"},{"key":"bibr5-11782218221112502","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.17.196287"},{"key":"bibr6-11782218221112502","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2006.11.009"},{"key":"bibr7-11782218221112502","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02539.x"},{"key":"bibr8-11782218221112502","first-page":"15","volume":"18","author":"Hoseini F","year":"2010","journal-title":"J Yazd Univ Med Sci"},{"key":"bibr9-11782218221112502","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.05.014"},{"key":"bibr10-11782218221112502","unstructured":"Sadock B, Sadock V, Pedro R. Substance-related disorders. In: Kaplan and Sadock\u2019s comprehensive textbook of psychiatry. 9th ed. Lippincott Williams & Wilkins; 2009:141-174."},{"key":"bibr11-11782218221112502","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1998.83.1.295"},{"key":"bibr12-11782218221112502","first-page":"55","volume":"11","author":"Moeini M","year":"2014","journal-title":"J School Public Health Inst Public Health Res"},{"key":"bibr13-11782218221112502","first-page":"115","volume":"1","author":"Riahi A","year":"2015","journal-title":"J Health Based Res"},{"key":"bibr14-11782218221112502","first-page":"30","volume":"22","author":"Mohebi MD","year":"2015","journal-title":"Avicenna J Clin Med"},{"key":"bibr15-11782218221112502","doi-asserted-by":"publisher","DOI":"10.29252\/jnkums.5.5.S5.1145"},{"key":"bibr16-11782218221112502","first-page":"2034","volume":"9","author":"Afsar A","year":"2014","journal-title":"J Health Syst Res"},{"key":"bibr17-11782218221112502","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1994.10472259"},{"key":"bibr18-11782218221112502","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2011.642758"},{"key":"bibr19-11782218221112502","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(03)00024-2"},{"key":"bibr20-11782218221112502","doi-asserted-by":"publisher","DOI":"10.1111\/add.12333"},{"key":"bibr21-11782218221112502","first-page":"139","volume":"55","author":"Simoens S","year":"2005","journal-title":"Br J Gen Pract"},{"key":"bibr22-11782218221112502","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2013.02.008"},{"key":"bibr23-11782218221112502","first-page":"28","volume":"1","author":"Fakhraie S","year":"2007","journal-title":"Addict J"},{"key":"bibr24-11782218221112502","volume-title":"Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: A Treatment Improvement Protocol (TIP 40)","author":"McNicholas L.","year":"2004"}],"container-title":["Substance Abuse: Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11782218221112502","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11782218221112502","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11782218221112502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:30:31Z","timestamp":1777692631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11782218221112502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":24,"alternative-id":["10.1177\/11782218221112502"],"URL":"https:\/\/doi.org\/10.1177\/11782218221112502","relation":{},"ISSN":["1178-2218","1178-2218"],"issn-type":[{"value":"1178-2218","type":"print"},{"value":"1178-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"11782218221112502"}}